Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Consensus "Moderate Buy": Thirteen brokerages covering Arcturus have an average recommendation of "Moderate Buy" (1 sell, 3 hold, 8 buy, 1 strong buy) with an average 12‑month price target of $29.50.
• Recent results and analyst moves are mixed: the company missed Q results (EPS -$1.03 vs. -$0.92 estimate; revenue $7.2M vs. $14.32M expected), and several firms sharply cut targets (e.g., Piper Sandler $72→$25, Citi $66→$21) even as others initiated coverage with buy ratings.
• Valuation and ownership: ARCT trades around $8.46 with a market cap of about $240M and a 12‑month range of $5.85–$24.17, and institutional investors own roughly 94.54% of the shares.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the thirteen brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $29.50.

Several equities analysts recently issued reports on the stock. Roth Mkm assumed coverage on shares of Arcturus Therapeutics in a research report on Thursday, January 22nd. They set a "buy" rating and a $20.00 price target on the stock. Piper Sandler reduced their price target on shares of Arcturus Therapeutics from $72.00 to $25.00 and set an "overweight" rating on the stock in a research report on Wednesday, March 4th. Citigroup reduced their price target on shares of Arcturus Therapeutics from $66.00 to $21.00 and set a "buy" rating on the stock in a research report on Thursday, March 5th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Arcturus Therapeutics in a research report on Wednesday, January 21st. Finally, B. Riley Financial assumed coverage on shares of Arcturus Therapeutics in a research report on Wednesday, March 18th. They set a "buy" rating and a $22.00 price target on the stock.

Arcturus Therapeutics Trading Up 1.2%

ARCT stock opened at $8.46 on Tuesday. The firm's 50-day moving average price is $7.50 and its two-hundred day moving average price is $9.18. Arcturus Therapeutics has a 12-month low of $5.85 and a 12-month high of $24.17. The stock has a market capitalization of $240.43 million, a price-to-earnings ratio of -3.55 and a beta of 2.44.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its quarterly earnings data on Tuesday, March 3rd. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.92) by ($0.11). Arcturus Therapeutics had a negative net margin of 80.19% and a negative return on equity of 29.13%. The firm had revenue of $7.20 million during the quarter, compared to analysts' expectations of $14.32 million. Equities analysts predict that Arcturus Therapeutics will post -2.22 EPS for the current year.

Hedge Funds Weigh In On Arcturus Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Osaic Holdings Inc. grew its holdings in Arcturus Therapeutics by 51.8% in the second quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 738 shares during the period. BNP Paribas Financial Markets grew its holdings in Arcturus Therapeutics by 163.4% in the second quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company's stock worth $54,000 after purchasing an additional 2,586 shares during the period. Compagnie Lombard Odier SCmA purchased a new stake in Arcturus Therapeutics in the third quarter worth about $111,000. CANADA LIFE ASSURANCE Co grew its holdings in Arcturus Therapeutics by 27.5% in the third quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company's stock worth $136,000 after purchasing an additional 1,567 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Arcturus Therapeutics by 42.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,760 shares of the biotechnology company's stock worth $143,000 after purchasing an additional 2,313 shares during the period. Hedge funds and other institutional investors own 94.54% of the company's stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus's approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company's pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.